MX2016000220A - Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. - Google Patents

Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.

Info

Publication number
MX2016000220A
MX2016000220A MX2016000220A MX2016000220A MX2016000220A MX 2016000220 A MX2016000220 A MX 2016000220A MX 2016000220 A MX2016000220 A MX 2016000220A MX 2016000220 A MX2016000220 A MX 2016000220A MX 2016000220 A MX2016000220 A MX 2016000220A
Authority
MX
Mexico
Prior art keywords
regulation
glucose metabolism
cgrp antibodies
optionally
agent
Prior art date
Application number
MX2016000220A
Other languages
English (en)
Inventor
A Latham John
Baker Brian
T L Smith Jeffrey
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of MX2016000220A publication Critical patent/MX2016000220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

|La presente descripción proporciona métodos para la prevención o tratamiento de trastornos metabólicos. En modalidades ejemplares, se proporcionan métodos para administrar un anticuerpo anti-CGRP, opcionalmente en combinación con un segundo agente, en donde se incrementa la utilización de glucosa periférica y/o hepática, para de esta manera prevenir o tratar enfermedades y trastornos asociados con la resistencia a insulina. También se proporcionan composiciones que comprenden un anticuerpo anti-CGRP, opcionalmente en combinación con un segundo agente, que son adecuadas para la administración para incrementar la utilización de glucosa periférica y/o hepática y de esta manera prevenir o tratar enfermedades y trastornos asociados con la resistencia a insulina.
MX2016000220A 2013-07-03 2014-07-03 Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. MX2016000220A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842745P 2013-07-03 2013-07-03
US201461982611P 2014-04-22 2014-04-22
PCT/US2014/045389 WO2015003122A2 (en) 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
MX2016000220A true MX2016000220A (es) 2016-08-18

Family

ID=52144290

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000220A MX2016000220A (es) 2013-07-03 2014-07-03 Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.

Country Status (14)

Country Link
US (1) US20150017166A1 (es)
EP (1) EP3016684B1 (es)
JP (4) JP6502337B2 (es)
KR (1) KR102476907B1 (es)
CN (1) CN105492026A (es)
AU (2) AU2014285052B2 (es)
CA (1) CA2916980C (es)
ES (1) ES2911690T3 (es)
IL (1) IL243355A0 (es)
MX (1) MX2016000220A (es)
NZ (1) NZ754427A (es)
SG (2) SG10201906172XA (es)
TW (2) TWI712419B (es)
WO (1) WO2015003122A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916980C (en) * 2013-07-03 2023-02-21 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10392434B2 (en) 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
KR20240049275A (ko) 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE126395T1 (de) * 1989-01-03 1995-08-15 Motorola Inc Verfahren zum herstellen von löthöckern hoher dichte und ein substratsockel für löthöcker hoher dichte.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
AU620727B2 (en) * 1989-07-10 1992-02-20 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
CN1617737A (zh) * 2001-11-26 2005-05-18 普罗特米克斯公司 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
EP2162469A4 (en) 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
HUE043782T2 (hu) 2007-05-21 2019-09-30 Alderbio Holdings Llc IL-6 elleni antitestek és alkalmazásuk
AR086515A1 (es) * 2011-05-20 2013-12-18 Alderbio Holdings Llc Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea
SI3495392T1 (sl) * 2011-05-20 2021-11-30 H. Lundbeck A/S Sestavki proti CGRP in uporaba le-teh
CA2916980C (en) * 2013-07-03 2023-02-21 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies

Also Published As

Publication number Publication date
JP2018168186A (ja) 2018-11-01
JP6502337B2 (ja) 2019-04-17
TWI753471B (zh) 2022-01-21
CA2916980C (en) 2023-02-21
WO2015003122A3 (en) 2015-03-19
AU2014285052A1 (en) 2016-02-11
KR20160029822A (ko) 2016-03-15
NZ754427A (en) 2021-12-24
EP3016684A4 (en) 2017-06-07
NZ715834A (en) 2021-11-26
IL243355A0 (en) 2016-03-31
JP2019112455A (ja) 2019-07-11
SG10201906172XA (en) 2019-08-27
EP3016684A2 (en) 2016-05-11
TW201536316A (zh) 2015-10-01
AU2014285052B2 (en) 2019-09-12
CN105492026A (zh) 2016-04-13
SG11201510618YA (en) 2016-03-30
KR102476907B1 (ko) 2022-12-13
ES2911690T3 (es) 2022-05-20
TWI712419B (zh) 2020-12-11
CA2916980A1 (en) 2015-01-08
JP2016528198A (ja) 2016-09-15
JP2020158525A (ja) 2020-10-01
WO2015003122A2 (en) 2015-01-08
AU2019279945B2 (en) 2022-01-20
TW202106335A (zh) 2021-02-16
AU2019279945A1 (en) 2020-01-16
US20150017166A1 (en) 2015-01-15
EP3016684B1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PH12020500352A1 (en) Therapeutic uses of empagliflozin
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
WO2014120619A3 (en) Compositions and methods of use in treating metabolic disorders
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX364220B (es) Metodos de tratamientos de fibrosis.
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2012174224A3 (en) Methods for administering nucleic acid-based therapeutics
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
BR112014029308A2 (pt) um método de melhorar a função hepática
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
MX2015008676A (es) Formulaciones de nanoparticulas de metadichol, liquidas y en gel.
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: H. LUNDBECK A/S.*